Journal of women's health (2002) · 2026
Prevalence of Elevated Liver-Associated Enzymes in Women Aged 40-65 Years in the United States Overall, and With and Without Metabolic Dysfunction-Associated Steatotic Liver Disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cui Yadong Adam, Storfer-Isser Amy, Pierre-Louis Bosny, Martins Karla, Snijder Robert, Han Wei, Chin-Kon-Sung Ulrich, Robinson Noah Jamie
Аннотация
BACKGROUND: We estimated the prevalence of elevated liver-associated enzymes (LAEs) in a nationally representative sample of women aged 40-65 years in the United States, overall and by menopausal status or by metabolic dysfunction-associated steatotic liver disease (MASLD).
METHODS: This descriptive study used cross-sectional data from the National Health and Nutrition Examination Survey collected from 1999/2000 to 2017/March 2020. The primary study endpoint was the weighted prevalence of elevated LAEs, measured by alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3× the upper limit of normal (ULN). Prespecified secondary endpoints included the prevalence of elevated LAEs by different definitions and by menopause and MASLD status.
RESULTS: The study included 11,443 women aged 40-65 years (mean age 51.7 years) from surveys representing the general population: 53.3% postmenopausal, 33.8% premenopausal, and 12.9% with unknown menopausal status. The prevalence of MASLD was estimated at 29.5% (95% confidence interval [CI]: 27.7-31.4); this was higher in postmenopausal women (34.4%, 95% CI: 32.0-36.9) than premenopausal women (22.7%, 95% CI: 20.2-25.4). The estimated prevalence of ALT or AST >3× ULN was 0.87% (95% CI: 0.68-1.11); this was similar for premenopausal (0.84%, 95% CI: 0.48-1.36) and postmenopausal (0.91%, 95% CI: 0.67-1.21) women, but higher for women with MASLD (1.50%, 95% CI: 0.87-2.40) than those without MASLD (0.25%, 95% CI: 0.09-0.56).
CONCLUSIONS: This study provides prevalence estimates of elevated LAEs in middle-aged women in the US general population. MASLD was common, and ALT or AST >3× ULN was more prevalent in women with than without MASLD.
METHODS: This descriptive study used cross-sectional data from the National Health and Nutrition Examination Survey collected from 1999/2000 to 2017/March 2020. The primary study endpoint was the weighted prevalence of elevated LAEs, measured by alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3× the upper limit of normal (ULN). Prespecified secondary endpoints included the prevalence of elevated LAEs by different definitions and by menopause and MASLD status.
RESULTS: The study included 11,443 women aged 40-65 years (mean age 51.7 years) from surveys representing the general population: 53.3% postmenopausal, 33.8% premenopausal, and 12.9% with unknown menopausal status. The prevalence of MASLD was estimated at 29.5% (95% confidence interval [CI]: 27.7-31.4); this was higher in postmenopausal women (34.4%, 95% CI: 32.0-36.9) than premenopausal women (22.7%, 95% CI: 20.2-25.4). The estimated prevalence of ALT or AST >3× ULN was 0.87% (95% CI: 0.68-1.11); this was similar for premenopausal (0.84%, 95% CI: 0.48-1.36) and postmenopausal (0.91%, 95% CI: 0.67-1.21) women, but higher for women with MASLD (1.50%, 95% CI: 0.87-2.40) than those without MASLD (0.25%, 95% CI: 0.09-0.56).
CONCLUSIONS: This study provides prevalence estimates of elevated LAEs in middle-aged women in the US general population. MASLD was common, and ALT or AST >3× ULN was more prevalent in women with than without MASLD.